Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo
dc.contributor.author | Cassano, Giovanni B. | en_US |
dc.contributor.author | Toni, Cristina | en_US |
dc.contributor.author | Petracca, Alberto | en_US |
dc.contributor.author | Deltito, Joseph | en_US |
dc.contributor.author | Benkert, Otto | en_US |
dc.contributor.author | Curtis, George C. | en_US |
dc.contributor.author | Hippius, H. | en_US |
dc.contributor.author | Maier, Wolfgang | en_US |
dc.contributor.author | Shera, David | en_US |
dc.contributor.author | Klerman, Gerald | en_US |
dc.date.accessioned | 2006-04-10T18:17:45Z | |
dc.date.available | 2006-04-10T18:17:45Z | |
dc.date.issued | 1994-03 | en_US |
dc.identifier.citation | Cassano, Giovanni B., Toni, Cristina, Petracca, Alberto, Deltito, Joseph, Benkert, Otto, Curtis, George, Hippius, H., Maier, Wolfgang, Shera, David, Klerman, Gerald (1994/03)."Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo." European Neuropsychopharmacology 4(1): 47-53. <http://hdl.handle.net/2027.42/31721> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T26-475JRKT-DY/2/8935bc1457992bd2feb500480252c19a | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/31721 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8204996&dopt=citation | en_US |
dc.description.abstract | Side effects play a significant role in the selection of drugs to be used in panic disorder/agoraphobia whose polyphobic symptomatology often includes a suspiciousness about taking drugs and a fear of undesired side effects which may lead to the refusal of treatment.The safety, side effects and patients' acceptance of alprazolam and imipramine versus placebo were evaluated in 1168 subjects with panic disorder/agoraphobia who had been enrolled in the second phase of the Upjohn World Wide Panic Study. Side effects that worsened over baseline to a greater extent with alprazolam than with imipramine and placebo were sedation, fatigue/weakness, memory problems, ataxia and slurred speech. In the imipramine group blurred vision, tachycardia/palpitations, insomnia, sleep disturbance, excitement/nervousness, malaise, dizziness/faintness, headache, nausea/vomiting and decrease in appetite were worse than in the other groups. In the placebo group the anxious symptoms were most prominent. The highest level of compliance was shown in the alprazolam-treated group and the lowest in the placebo-treated group. Strong predictors of side effects were not observed.If a side effect profile is known, it will be easier for a clinician to choose the right drug and the appropriate management by taking into account compliance, safety and efficacy in each patient under treatment. Further information about side effects in long-term maintenance treatment would be of great clinical pertinence in ensuring safety and enhancing patients' quality of life. | en_US |
dc.format.extent | 623220 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Psychiatry | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Department of Psychiatry, Med. Inn Building 444, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0804, USA | en_US |
dc.contributor.affiliationother | Psychiatric Clinic II, University of Pisa, via Roma 67, 56100, Pisa, Italy | en_US |
dc.contributor.affiliationother | Psychiatric Clinic II, University of Pisa, via Roma 67, 56100, Pisa, Italy | en_US |
dc.contributor.affiliationother | Psychiatric Clinic II, University of Pisa, via Roma 67, 56100, Pisa, Italy | en_US |
dc.contributor.affiliationother | Cornell University Medical College, 21 Bloomingdale Road, White Plains, NY 10605, USA | en_US |
dc.contributor.affiliationother | Department of Psychiatry, University of Mainz, Postfach 3960, Untere Zahlbacher Street 8, 6500, Mainz, Germany | en_US |
dc.contributor.affiliationother | Psychiatric Clinic, University of Munich, Nussbaumstrasse 7, 8000, Munich 2, Germany | en_US |
dc.contributor.affiliationother | Department of Psychiatry, University of Mainz, Postfach 3960, Untere Zahlbacher Street 8, 6500, Mainz, Germany | en_US |
dc.contributor.affiliationother | New England Biomedical Research Foundation, Cambridge, MA 02238-2732, USA | en_US |
dc.contributor.affiliationother | Cornell University Medical College, 21 Bloomingdale Road, White Plains, NY 10605, USA | en_US |
dc.identifier.pmid | 8204996 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/31721/1/0000659.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0924-977X(94)90314-X | en_US |
dc.identifier.source | European Neuropsychopharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.